跳至主要内容
临床试验/NCT02953431
NCT02953431已完成不适用

Increased Lung Volume as Controller Therapy for Asthma

University of Vermont2 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2018年5月7日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
60
试验地点
2
主要终点
Change in impedance of lung in response to methacholine measured by forced oscillation

研究概览

简要总结

This is an early phase clinical trial to test the efficacy of elevating lung volume with positive expiratory pressure (CPAP) as a controller therapy for asthma in patients with a BMI ≥ 30 kg/m2.

There will be two phases to this trial.

Phase I:

In the first phase we will determine the optimal duration of CPAP that is effective as a controller therapy in asthma. Up to 9 participants will complete this this phase.

Phase II:

The 2nd phase will be a randomized double-blinded controlled trial of Sham CPAP versus CPAP 10 (using the duration of CPAP determined in phase I) as a controller therapy for asthma, and also to determine the effect o airway reactivity in healthy people with a BMI 30 kg/m2 and above. Twenty people with asthma and twenty controls will complete this phase.

详细描述

The effect of 10 versus 0 cmH2O CPAP on airways responsiveness to inhaled methacholine will be studied using an adaptive "3+3" phase I/II study design.

Dose Titration Phase (phase I):

The efficacy of 8 hours of CPAP on airway responsiveness will be tested in three subjects.

Efficacy will be defined as a 25% improvement in the impedance response to methacholine in all three subjects. If this occurs in all subjects, shorter durations of CPAP will be studied (4 hours then one hour).

Conversely, if "dose escalation" is required, 3 nights, then 7 nights of CPAP will be studied.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • FEV1 < 60 % predicted
  • Other significant disease that in the opinion of the investigator would interfere with study.
  • Inability to perform required testing.
  • Smoking within last 6 months.
  • ≥ 20 pack year smoking history
  • Inability to provide informed consent
  • Known obstructive sleep apnea/ high likelihood of obstructive sleep apnea
  • Asthma exacerbation in the prior 6 weeks
  • Stoke or heart attack in the prior 3 months
  • Known aortic aneurysm
  • Renal failure
  • A known severe heart, vascular, liver, renal, or hematological disease
  • Active allergic rhinitis
  • Recent eye surgery (within the last month)

结局指标

主要结局

Change in impedance of lung in response to methacholine measured by forced oscillation

时间窗: Through study completion, an average of one week

Average change in impedance in response to methacholine in participants assigned to Sham CPAP versus CPAP 10

次要结局

  • Change in spirometric lung function (FEV1 and FVC)(Through study completion, an average of one week)
  • Change in asthma control(Through study completion, an average of one week)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Anne Dixon

Professor of Medicine

University of Vermont

研究点 (2)

Loading locations...

相似试验

Increased Lung Volume as Controller Therapy for... | 临床试验